CAS: 119567-79-2; Taribavirin

该化合物是一种抗病毒化合物,主要研究其潜在用途,治疗病毒感染,特别是丙型肝炎病毒(HCV)造成的病毒感染.它属于核肺类仿仿仿天然核素结构的类类,它模仿天然核素结构,从而干扰病毒复制.维拉米迪因化学结构具有改进的脊髓核素脊椎,它比以前更稳定,更具有生物利用率.该化合物展示了一种行动机制,它涉及抑制病毒性RNA聚合酶,最终导致病毒负荷减少.Viramidiine在各种临床前科和临床研究中得到了评估,展示了有希望的抗病毒活动.其药性肿瘤特征表明,它具有有利的吸收和分布特征,尽管具体细节可能因配方和管理途径而不同.与许多抗病毒剂一样,维拉米迪因的功效和安全特征对于其治疗应用至关重要,并且正在进行的研究继续探索其增强抗病毒效应的混合疗法的潜力.

结构式图片

MSDS等安全信息

    上下游产品

    (2R,3S,4R,5R)-2-(羟基甲基)-5-[3-(甲氧基亚胺甲酰基)-1,2,4-三唑-1-基]四氢呋喃-3,4-二醇 Methyl 1-β-D-Ribofuranosyl-1,2,4-Triazole-3-Carboximidate 120362-25-6

    合成工艺路线路线简述

      📜(2R,3S,4R,5R)-2-(羟基甲基)-5-[3-(甲氧基亚胺甲酰基)-1,2,4-三唑-1-基]四氢呋喃-3,4-二醇,氨,甲醇 反应生成利巴韦林
      参考文献:Kini,Ganesh D.;Robins,Roland K.;Avery,Thomas L.,J. Med. Chem.,32,(1989) N,C. 1447-1449
      标题:Kini,Ganesh D.;Robins,Roland K.;Avery,Thomas L.,J. Med. Chem.,32,(1989) N,C. 1447-1449

      海关参考信息

      专利信息


      专利号:WO-2022226312-A1
      优先权日:2021-04-22
      标 题:Combination nucleotide pool depletion for treatment of viral infections and cancers
      发明人:KUMAR VIKRAM; HESSON DAVID; DEMAREST JAMES
      权利人:CLEAR CREEK BIO INC
      摘要:The invention provides methods of treating cancers and viral infections by providing a combination of agents that inhibit both nucleotide synthesis and nucleotide salvage in the cells of a subject to prevent cancer proliferation and viral replication. The invention provides methods of depleting nucleotide pools by using both inhibitors of dihydroorotate dehydrogenase (DHODH), such as brequinar, which block synthesis of pyrimidine-based nucleotides, in combination of one or more nucleotide salvage inhibitors, for example deoxycytidine kinase (dCK) inhibitors, Equilibrative nucleoside transporter (ENT) inhibitors, and Uridine-cytidine kinase (UCK) inhibitors, which inhibit salvage of purine and/or pyrimidine-based nucleotides or nucleosides

      专利号:US-11649285-B2
      优先权日:2016-08-03
      标题 :Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy
      发明人:KALABOKIS VASSILIOS; WANG JINGHUA; WU GUOPING; BAZAN JOSE FERNANDO; VALLEY CHRISTOPHER CARLIN
      权利人:BIO TECHNE CORP
      摘要:The ligand for VISTA is identified (VSIG3) as well as the use of this ligand and receptor interaction in the identification or synthesis of a VSIG3 agonist or antagonist compounds, preferably antibodies, polypeptides and fusion proteins which agonize or antagonize the effects of VSIG3 and/or VISTA and/or the VSIG3/VISTA interaction. These antagonists may be used to suppress VSIG3/VISTA's suppressive effects on T cell immunity, and more particularly used in the treatment of cancer, or infectious disease. These agonist compounds may be used to potentiate or enhance VSIG3/VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity, such as in the treatment of autoimmunity, allergy or inflammatory conditions. Screening assays for identifying these agonists and antagonist compounds are also provided.

      专利号:WO-2011106929-A1
      优先权日:2010-03-02
      标题:Inhibitors of hepatitis c virus ns5b polymerase
      发明人:MCCOMAS CASEY CAMERON; LIVERTON NIGEL J; HABERMANN JOERG; KOCH UWE; NARJES FRANK; LI PENG; PENG XUANJIA; SOLL RICHARD; WU HAO
      权利人:MERCK SHARP & DOHME; ANGELETTI P IST RICHERCHE BIO; MCCOMAS CASEY CAMERON; LIVERTON NIGEL J; HABERMANN JOERG; KOCH UWE; NARJES FRANK; LI PENG; PENG XUANJIA; SOLL RICHARD; WU HAO
      摘要:Compounds of formula I that are used as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infection and for inhibiting HCV viral replication and /or viral production in a cell-based system.

      专利号:US-9493461-B2
      优先权日:2013-02-07
      标 题 :Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis C
      发明人:DAI XING; LIU HONG; PALANI ANANDAN; HE SHUWEN; LAI ZHONG; NARGUND RAVI; MARCANTONIO KAREN; XIAO DONG; BROCKUNIER LINDA L; ZORN NICOLAS; DANG QUN; PENG XUANJIA; LI PENG
      权利人:MERCK SHARP & DOHME
      摘要:The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

      专利号:US-9573939-B2
      优先权日:2011-09-08
      标题:Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
      发明人:MCCOMAS CASEY C; LIVERTON NIGEL J; HABERMANN JOERG; KOCH UWE; NARJES FRANK; LI PENG; PENG XUANJIA; SOLL RICHARD; WU HAO; PALANI ANANDAN; DAI XING; LIU HONG; HE SHUWEN; DANG QUN
      权利人:MCCOMAS CASEY C; LIVERTON NIGEL J; HABERMANN JOERG; KOCH UWE; NARJES FRANK; LI PENG; PENG XUANJIA; SOLL RICHARD; WU HAO; PALANI ANANDAN; DAI XING; LIU HONG; HE SHUWEN; DANG QUN; MERCK SHARP & DOHME; MSD ITALIA SRL
      摘要:The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

      专利号:WO-2011106986-A1
      优先权日:2010-03-02
      标题:Inhibitors of hepatitis c virus ns5b polymerase
      发明人:MCCOMAS CASEY CAMERON; LIVERTON NIGEL J; SOLL RICHARD; LI PENG; PENG XUANJIA; WU HAO
      权利人:MERCK SHARP & DOHME; MCCOMAS CASEY CAMERON; LIVERTON NIGEL J; SOLL RICHARD; LI PENG; PENG XUANJIA; WU HAO
      摘要:Compounds of formula (I) that are used as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and /or viral production in a cell-based system. Wherein Z, R 30 , R 40 , R 50 and R 60 of compounds of formula (I) are herein defined as in the description.

      供应商参考报价(招募中)

      品牌试剂参考报价(招募中)

      📌 第三方产品分析报告

      ✅ COA系统入驻 | 共享模式

      主要参考文献


      1: Konstantinova ID, Fateev IV, Galegov GA, Deriabin PG, Botikov AG, Muzyka IS, L'vov DK, Miroshnikov AI. [The arsenolysis reaction in the biotechnological method of synthesis of the ribavirin. Inhibition of reproduction of influenza A virus with the combination of ribavirin and ozeltamivir in experiments in vitro and in vivo]. Bioorg Khim. 2013 Sep-Oct;39(5):594-603. Russian. Russian. doi: 10.3851/IMP2308. Epub 2012 Sep 5. . Randomised clinical trial: pre-dosing with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment-naïve patients with chronic hepatitis C genotype 1. Aliment Pharmacol Ther. 2012 Aug;36(4):370-8. doi: 10.1111/j.1365-2036.2012.05188.x. Epub 2012 Jun 19.
      5: Deming P, Arora S. Taribavirin in the treatment of hepatitis C. Expert Opin Investig Drugs. 2011 Oct;20(10):1435-43. doi: 10.1517/13543784.2011.606214. Epub 2011 Aug 20. Review. doi: 10.3851/IMP1734. doi: 10.1002/hep.23957. doi: 10.1002/hep.23827. doi: 10.1007/s12539-009-0039-4. Epub 2009 Aug 7. Polish. doi: 10.1016/j.jhep.2009.10.017. Epub 2009 Oct 29. doi: 10.1016/j.jhep.2009.10.015. Epub 2009 Oct 23. doi: 10.1016/j.cld.2009.05.006. doi: 10.1002/hep.23073. doi: 10.1517/14656560802594459 . Review. doi: 10.1016/j.antiviral.2008.01.003. Epub 2008 Feb 4. Review.
      17: Benhamou Y. Anemia and clinical outcomes in hepatitis C. J Hepatol. 2007 Jul;47(1):7-9. Epub 2007 Apr 20. Epub 2007 Mar 12.

      合成参考文献


      参考文献:10.1007/s11894-004-0030-5
      摘要:Dev A, Patel K, McHutchison JG. New therapies for chronic hepatitis C virus infection. Curr Gastroenterol Rep. 2004 Feb;6(1):77–86. doi: 10.1007/s11894-004-0030-5.
      📝 需求与反馈
      尽可能描述清楚需求与问题信息
      ×

      通知